ArticleThe Journal of clinical investigation2025

Epigenetic therapy sensitizes anti-PD-1 refractory head and neck cancers to immunotherapy rechallenge.

Tingting Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.